Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 26Gynecologic 13Thoracic 9Gastrointestinal 9Dermatologic 6Genitourinary 5Lymphoid 3Plasma cell 2Other hematologic neoplasm 2CNS 2Sarcoma 1NET 1Myeloid 1Head & Neck 1Endocrine 1

Conditions

Urogenital Neoplasms 1Ovarian Neoplasms 1Neuroendocrine Tumors 1Multiple Myeloma 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Fluorodeoxyglucose F18 3Magnetic Resonance Spectroscopy 2Cyclophosphamide 2tivozanib 1romidepsin 1pembrolizumab 1gadoteridol 1gadoterate meglumine 1gadolinium ethoxybenzyl DTPA 1gadodiamide 1gadobutrol 1gadobenic acid 1fludarabine phosphate 1fludarabine 1entrectinib 1atezolizumab 1alectinib 1aldesleukin 1Specimen Handling 1Quality of Life 1Patient Reported Outcome Measures 1Neuropsychological Tests 1Molecular Diagnostic Techniques 1Lactones 1Interleukin-13 1Immunotherapy 1FAPI-46 1Drug Therapy 1Depsipeptides 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Breast Neoplasms × aldesleukin × NET × Clear all
NCT03412877 2026-05-22

Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting
285 enrolled
BreastEndocrineGynecologicNETPlasma cellThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Multiple Myeloma, Ovarian Neoplasms, Urogenital Neoplasms, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡